

INDIA PHARMA 2022

7th International Conference on Pharmaceutical Industry
 25th- 27th April 2022, Dr Ambedkar International Centre, New Delhi

Vision 2047: Transformative roadmap for the future

Draft Conference Programs

TIME	EVENT
DAY 1, 25th April 2022	
1000-1130	Inaugural Session and Awards Ceremony
1200-1400	Pharma CEOs Roundtable with Hon'ble Minister
1500-1700	Medical Devices CEOs Roundtable with Hon'ble Minister
1730-1900	Drug Regulatory Meet
DAY 2, 26th April 2022	
1000-1130	Theme SESSION: Indian Pharma: Vision 2047
	<p>Session Brief:</p> <ul style="list-style-type: none"> i. Where India Lifesciences Sector will be in 2047? ii. What Sectors/technologies India will/should be leading in? iii. What areas will India have global champions in- Innovative drugs, Biologicals, complex generics/biosimilars? Or any other vertical iv. How to continue India's dominance as Pharmacy of the World, v. How can India come in top 3 countries for Patented medicines discovery & exports, vi. How do we move from CT to real world evidence, to healthcare delivery at doorstep vii. What Institutional capabilities will India have by then? Reforms needed? <p>Chair: Mr Rajiv Kumar, Vice Chairman, NITI Aayog Moderator: Mr Jaidev Rajpal, Partner, McKinsey ©</p> <p>Government Participants:</p> <ul style="list-style-type: none"> • Ms S Aparna, Secretary, Department of Pharmaceuticals, Gol • Mr Rajesh Bhushan, Secretary, Ministry of Health & Family Welfare • Mr Anurag Jain, Secretary, DPIIT • Mr BVR Subrahmanyam, Secretary DOC <p>Panellists:</p> <ul style="list-style-type: none"> • Mr Pankaj Patel, Chairman, Zydus Cadila Healthcare© • Mr Siddharth Mittal, CEO, Biocon © • Mr S Sridhar, Managing Director, Pfizer © • Mr Gagan Singh Bedi, Managing Director, AstraZeneca © • Dr Viranchi Shah, President, IDMA © • Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech • Mr Samir Mehta, Chairman, Torrent Pharma
1130-1145	BREAK

1145-1315	SESSION 2: Building Resilient Supply Chains
	<p>Session Brief: COVID-19 has emphasized the importance of strong healthcare and pharmaceutical ecosystem for India. Constant demand for drugs and the expectation to deliver them on time put a lot of pressure on pharma supply chains. However, it also brought to the fore key challenges such as reliance on China for key APIs and KSMs, volatile & escalating cost and meeting new healthcare needs. On the other hand, the pandemic stressed the reliance on drugs made in India and unlocked new avenues of growth for the Indian Pharmaceuticals industry. To seize these new opportunities, the Indian pharmaceuticals sector should focus on strengthening and diversifying its supply chain network. India has taken already taken few steps to address the challenges and seize this opportunity; notably the PLI Scheme. This is India's moment to transform from the Pharmacy of the world in its real sense by emerging as a self-sufficient reliable global supplier of quality and affordable drugs to the world. Pharma Supply Chain has been in the spotlight for last 2 years for good and bad reasons. We will attempt to understand the factors that lead to global supply chain disruption and what measures we are taking to make it robust and resilient going forward.</p> <p>Key Discussion Points:</p> <ul style="list-style-type: none"> • Key learnings from COVID-19 in making India a reliable supply chain partner • Need for diversified supply chain to ensure consistent supplies and managed volatility • Building visible, reliable and robust supply chain for domestic market • What are the major challenges being faced in supply chain while exporting and domestic supply? • Is Industry 4.0 and digitization the next game changer • Impact of Geo-political events on supply chain namely localization of manufacturing, international transport • Understand GATISHAKTI plans • Support required from government for consistency and predictability in policy <p>Introductory remarks: Ms S Aparna, Secretary, Department of Pharmaceuticals, GoI Chair: Mr Anurag Jain, Secretary DPIIT Moderator: Mr Nickil, Senior Partner, KPMG © Co-Moderator: Sudarshan Jain, SG, IPA ©</p> <p>Government panelists:</p> <ol style="list-style-type: none"> 1. Ms Nidhi Mani Tripathi, JS, Department of Commerce 2. Dr Mandeep Bhandari, Joint Secretary, MoH & FW, GoI 3. Shri Satyendra Kumar Mishra, Joint Secy. (SKM), Ministry of Civil Aviation, GOI 4. Shri Gaurav Masaldan, Joint Secretary (Customs), Central Board of Indirect Taxes and Customs, Department of Revenue, Ministry of Finance, GOI 5. Sh. Vikram Singh, JS(Ports), Ministry of Ports Shipping and Waterways Division, GOI 6. Uday Bhaskar, DG, Pharmexcil © <p>Industry panelists:</p> <ol style="list-style-type: none"> 1. Mr Nilesh Gupta, MD, Lupin 2. Mr Vikrant Shrotiye, MD, Novo Nordisk, India © 3. Mr Raju Krishnaswamy, Sr. Director (SC), Abbott © 4. Mr Vickram Srivastava, SC, Sun Pharma © 5. Mr Nehal Vohra, Senior Vice President- Commercial, Biocon © 6. Mr K. G. Ananthakrishnan, SG, OPPI © 7. Mr Ajit Singh, Chairman, ACG Worldwide ©
1315-1400	LUNCH BREAK

1400-1530	SESSION 3: Evolving Health Tech Space: Some Success Stories
	<p>Session Brief: The start-up ecosystem is providing lot of opportunities to the entrepreneurs for novel products and technologies in the healthcare sector. This session proposes to present success stories of such entrepreneurs who have been able to commercialise their products and technology solutions. The entrepreneurs need a platform to present their work and their success story to the Government since both the Pharma and Medical Device Sector is regulated from the quality aspects. The session will deliberate on Opportunities, Challenges, Regulatory support needed and Taxation/Financial edge to be competitive globally for the start-ups</p> <p>Key Discussion Points:</p> <ul style="list-style-type: none"> • Presentation by Three AIML (Artificial and Machine based learning) Start-up's operating in India since 2016 and have created successful business models around it. <ul style="list-style-type: none"> - Brief profile of each start-up and their current market size - SIZE of the PRIZE: Potential these start-up's think India can achieve - Their plans for future growth and job creation they can support going forward • Suggestions on support needed by them to place India at the highest pedestal of the AI value chain by 2025 • What national digital strategies can be implemented/what existing laws and policies can be amended <p>Chair: Dr VK Paul, Member, NITI Aayog</p> <p>Introductory Remarks: Dr Srivari Chandrasekhar, Secretary, DST</p> <p>Moderator: Dr. Sarit Kumar Das, Professor, IIT Madras</p> <p>Government panellists:</p> <ul style="list-style-type: none"> • Dr Mandeep Bhandari, Joint Secretary, MoH & FW, GoI • Dr Manish Diwan – Head SPED, BIRAC © • Dr VG Somani, DCGI, CDSCO • Dr Chintan Vaishnav, Mission Director, Atal Innovation Mission <p>Industry panellists:</p> <ul style="list-style-type: none"> • Mr. Prashant Tandon, CEO & Founder Tata 1mg • Dr Prashant Patel, CEO & Co-Founder, Alveofit © • Mr Prashant Warier, CEO, QureAi • Mr Suthirth Vaidya, CEO & Co-Founder, Predible Health © • Mr Divyanu Gupta, CEO & Co-Founder, Housepital ©
1530- 1545	BREAK

1545-1715	SESSION 4: Ecosystem for R&D and Innovation: <i>Building Collaborations</i>
	<p>Session Brief:</p> <p>Life sciences in India have witnessed huge progress. India needs to give a boost to biopharma and pharma manufacturing (R&D, Digital Transformation, Green Tech and IP) by leveraging inherent and pre-existing strengths of Indian manufacturing in the bio-manufacturing and pharma space and catapult India into the global Research and Development and high value pharma space. The session will focus on deliberating on and defining the future roadmap to achieve the goal.</p> <ul style="list-style-type: none"> • Creating favourable regulatory environment to promote innovation • Deliberate how can we improve access to quality infrastructure for sustainable clinical trials • Strengthening Innovation clusters on the lines of mature global hubs like Boston and Singapore • Identify ways to increase R&D financing resources to encourage pharmaceutical R&D • Identify ways to build commercial ecosystem through industry-academia collaboration, promote outcome-based research and international collaborations • Develop accelerated pathways for R&D like in COVID times • Potential areas for research- How to decrease effluent load, AMR, etc • Moon-shot Futuristic areas- rare diseases, biologics, frontal medicines, genomics, advanced therapeutics, etc <p>Chair: Prof. Vijay Raghavan, PSA, GOI</p> <p>Moderator: Mr Rajeev Kakkad, Senior Partner, KPMG ©</p> <p>Government Panellists:</p> <ol style="list-style-type: none"> 1. Dr Balram Bhargava, ICMR 2. Ms S. Aparna, Secretary, Department of Pharmaceuticals, GoI 3. Dr. Rajesh Gokhale, Secretary, Department of Biotechnology 4. Dr. Shekhar C. Mande, Secretary, DSIR and CSIR <p>Panellists:</p> <ol style="list-style-type: none"> 1. Dr Kiran Mazumdar Shaw, Executive Chairperson, Biocon © 2. Dr Murtaza Khorakiwala, Managing Director, Wockhardt © 3. Mr Sarthak Ranade, MD, Janssen © 4. Mr Sanjay Murdeshwar, Managing Director, Novartis India© 5. Mr Jonathan Hunt, CEO and Managing Director, Syngene 6. Mr. Ajay Singla, Head of Global Injectables R&D and Scientific Affairs, Viatris © 7. Prof Anurag S Rathore, Professor, Department of Chemical Engineering, IIT Delhi © <p>Proposed technical speakers (International) Global Best Practices:</p> <ol style="list-style-type: none"> 1. Representative from BARDA, US Department of Health and Human Sciences 2. Dr J. Chris Love, Professor of Chemical Engineering, MIT © 3. Mr Tan Boon Khai, Chief Executive Officer, JTC Corporation Board, Ministry of Trade and Industry, Government of Singapore
1730-1930	Investors Forum: Pharma